Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial
Huijie Bian, Zhaohui Zheng, Wei Ding, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

CD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing Efferocytosis
Jianjun Lv, Hao Wang, Cong Zhang, et al.
Circulation Research (2024) Vol. 134, Iss. 2, pp. 165-185
Open Access | Times Cited: 28
Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer
Xiaoyan Yin, Wanqi Zhu, Xiaoyong Tang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 27
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma
Jiejie Geng, Liang Chen, Yufeng Yuan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 84
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease
Elisa Avolio, Michele Carrabba, Rachel Milligan, et al.
Clinical Science (2021) Vol. 135, Iss. 24, pp. 2667-2689
Open Access | Times Cited: 82
Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations
Valentina Bonetto, Laura Pasetto, Ilaria Lisi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 56
Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein
Robert J. Ragotte, David Pulido, Francesca R. Donnellan, et al.
mSphere (2021) Vol. 6, Iss. 4
Open Access | Times Cited: 54
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets
John Maher, David M. Davies
Cancers (2023) Vol. 15, Iss. 4, pp. 1171-1171
Open Access | Times Cited: 18
Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval
Hee Sun Choi, A Young Choi, Jeffrey B. Kopp, et al.
Journal of Korean Medical Science (2024) Vol. 39, Iss. 14
Open Access | Times Cited: 6
Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling
Eloara V.M. Ferreira, Rudolf K.F. Oliveira, Reinaldo Salomão, et al.
Infectious Disease Reports (2025) Vol. 17, Iss. 1, pp. 5-5
Open Access
Cyclophilin–CD147 interaction enables SARS-CoV-2 infection of human monocytes and their activation via Toll-like receptors 7 and 8
Gábor Tajti, Laura Gebetsberger, Gregor Pamlitschka, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody
David Scheim
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2558-2558
Open Access | Times Cited: 26
Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?
Manon Barthe, Leslie Hertereau, Noura Lamghari, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6253-6253
Open Access | Times Cited: 14
CD147: an integral and potential molecule to abrogate hallmarks of cancer
Alphonce M. K. Nyalali, Angela U. Leonard, Yongxiang Xu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
Lingli Xie, Ziying Zhang, Qian Wang, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 23
Going viral in the islet: mediators of SARS-CoV-2 entry beyond ACE2
Rohita Rangu, Pandora L. Wander, Breanne M. Barrow, et al.
Journal of Molecular Endocrinology (2022) Vol. 69, Iss. 2, pp. R63-R79
Open Access | Times Cited: 17
In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds
Maral Aminpour, Marco Cannariato, Jordane Preto, et al.
Computation (2022) Vol. 10, Iss. 4, pp. 51-51
Open Access | Times Cited: 16
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial
Huijie Bian, Liang Chen, Zhaohui Zheng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 9
Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection
Kwang Su Kim, Shoya Iwanami, Takafumi Oda, et al.
Life Science Alliance (2021) Vol. 4, Iss. 10, pp. e202101049-e202101049
Open Access | Times Cited: 21
Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis
Adrían V. Hernández, Alejandro Piscoya, Vinay Pasupuleti, et al.
The American Journal of Medicine (2022) Vol. 135, Iss. 11, pp. 1349-1361.e18
Open Access | Times Cited: 15
Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19
Hong Zhou, Wei‐Jian Ni, Wei Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants
Cheng‐Pu Sun, Chi-Wen Chiu, Ping‐Yi Wu, et al.
Molecular Therapy (2023) Vol. 31, Iss. 11, pp. 3322-3336
Open Access | Times Cited: 7
Immunological and metabolic characteristics of the Omicron variants infection
Jiejie Geng, Xu Yang, Kun Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Peter Schmidt, Jean Gong, Kristin Narayan, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 5, pp. 1365-1377
Open Access | Times Cited: 5
Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities
Ioanna E. Galani, Evangelos Andreakos
Seminars in Immunology (2021) Vol. 55, pp. 101522-101522
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top